Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Azetidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | SNCA | P37840 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | MMP2 | P08253 | 2/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrrolidine SCHEMBL2531422 | 0.96 | ALDH1A1 (0.46) | ALDH1A1LMNAHTTSMN1; SMN2KDM4E | |
| Piperidine SCHEMBL4867261 | 0.94 | ALDH1A1 (0.45) | ALDH1A1LMNAHTTSMN1; SMN2KDM4E | |
| Piperidine SCHEMBL631560 | 0.94 | ALDH1A1 (0.45) | ALDH1A1LMNAHTTSMN1; SMN2KDM4E | |
| Pyrrolidine SCHEMBL16241174 | 0.94 | ALDH1A1 (0.45) | ALDH1A1LMNAHTTSMN1; SMN2KDM4E | |
| Aziridine SCHEMBL5185484 | 0.94 | ALDH1A1 (0.50) | ALDH1A1LMNAHTTSMN1; SMN2KDM4E | |
| Piperidine SCHEMBL16927692 | 0.93 | ALDH1A1 (0.44) | ALDH1A1LMNAHTTSMN1; SMN2KDM4E | |
| Piperazine SCHEMBL7635861 | 0.92 | ALDH1A1 (0.49) | ALDH1A1LMNAHTTSMN1; SMN2KDM4E | |
| Piperazine SCHEMBL5875357 | 0.92 | ALDH1A1 (0.49) | ALDH1A1LMNAHTTSMN1; SMN2KDM4E | |
| Cyclopropane SCHEMBL2101355 | 0.89 | GAA (0.54) | ALDH1A1LMNAHTTSMN1; SMN2KDM4E | |
| Cyclohexane SCHEMBL27563472 | 0.89 | GAA (0.54) | ALDH1A1LMNAHTTSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4366829-A1 | PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-4326714-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| CN-111936503-B | Oxazine monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-116096723-A | Heterocyclic compounds useful as MAGL inhibitors | 豪夫迈·罗氏有限公司 | 2023-05-09 | — | — | CN | disclosed |
| WO-2023283453-A1 | PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2022223750-A1 | HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2022-10-27 | — | — | WO | disclosed |
| EP-4034541-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2022-08-03 | — | — | EP | disclosed |
| CN-114364684-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-109715613-A | Heterocyclic compound | 武田药品工业株式会社 | 2019-05-03 | — | — | CN | disclosed |